What is GL-0817 used for?

GL-0817 is indicated for Relapsed or refractory multiple myeloma.

GL-0817 is developed by Gliknik Inc..

What are the side effects of GL-0817?

Common side effects include Fatigue, Nausea, Diarrhea.

Last reviewed 2026-04-23 · How we verify

GL-0817

Gliknik Inc. · Phase 2 active Small molecule

GL-0817 is an anti-CD47 monoclonal antibody.

GL-0817 is an anti-CD47 monoclonal antibody. Used for Relapsed or refractory multiple myeloma.

At a glance

Generic name	GL-0817
Also known as	Biropepimut-S
Sponsor	Gliknik Inc.
Drug class	monoclonal antibody
Target	CD47
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

It works by blocking the CD47 signal that cancer cells use to evade the immune system, allowing the immune system to recognize and attack cancer cells.

Approved indications

Relapsed or refractory multiple myeloma

Common side effects

Fatigue
Nausea
Diarrhea

Key clinical trials

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GL-0817 CI brief — competitive landscape report
GL-0817 updates RSS · CI watch RSS
Gliknik Inc. portfolio CI